InvestSMART

Argenica Therapeutics Limited (ASX:AGN)

ALERT: Price-sensitive ASX Announcement for AGN
Current share price for AGN : $0.180 0.04 (28.57%)+
Announcement
Release
16 Jul 2026 8:27AM
Price at Release
$0.140
Full Release
download
Summary
Argenica Therapeutics Limited announced promising preclinical efficacy data for its drug candidate ARG-007 (xaranetide) in a rodent model of repeated mild traumatic brain injury (rmTBI), commonly known as concussion. The study, conducted with Curtin University and the Perron Institute for Neurological and Translational Science, demonstrated that a single low dose of xaranetide significantly reduced neuroinflammation, oxidative stress, and axonal damage in the brain. These findings highlight xaranetide's potential as a disease-modifying neuroprotective therapy that may not only alleviate symptoms but also target underlying pathways of brain injury. The results suggest that xaranetide can modulate multi-faceted injury mechanisms, supporting its development for treating repeated concussion injuries.
Key Points
  • ARG-007 (xaranetide) shows significant efficacy in reducing secondary injury effects in a concussion model.
  • Xaranetide reduces neuroinflammation, oxidative stress, and axonal damage.
  • Study undertaken with Curtin University and Perron Institute.
  • Single low dose administered 30 minutes after repeated mTBI.
  • Effects sustained for at least 11 days post-injury.
  • Potential as a disease-modifying neuroprotective therapy.
  • Modulates injury mechanisms beyond symptom alleviation.
  • Consistent with previous findings across TBI severity spectrum.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.